Benjamin F. Edwards & Company’s Sarepta Therapeutics SRPT Stock Holding History

Benjamin F. Edwards & Company’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$1K	Sell	6 -70	-92%	-$8.99K	﹤0.01%	2110
2024 Q1	$10K	Buy	76 +73	+2,433%	+$8.94K	﹤0.01%	1713
2023 Q4	$0	Buy	+3	New	+$288	﹤0.01%	2171
2023 Q1	–	Sell	-2,488	Closed	-$322K	–	1898
2022 Q4	$322K	Buy	+2,488	New	+$288K	0.01%	581
2020 Q1	–	Sell	-200	Closed	-$26K	–	1874
2019 Q4	$26K	Hold	200	–	–	﹤0.01%	1153
2019 Q3	$15K	Sell	200 -460	-70%	-$54.3K	﹤0.01%	1290
2019 Q2	$100K	Buy	660 +160	+32%	+$19.4K	0.01%	706
2019 Q1	$60K	Buy	500 +300	+150%	+$38.6K	0.01%	831
2018 Q4	$22K	Buy	+200	New	+$25K	﹤0.01%	1070
2017 Q4	–	Sell	-500	Closed	-$23K	–	1623
2017 Q3	$23K	Buy	+500	New	+$20K	﹤0.01%	949
2015 Q2	–	Sell	-1,100	Closed	-$15K	–	1199
2015 Q1	$15K	Hold	1,100	–	–	﹤0.01%	817
2014 Q4	$16K	Buy	1,100 +1,000	+1,000%	+$16.9K	﹤0.01%	723
2014 Q3	$2K	Buy	+100	New	+$2.26K	﹤0.01%	936

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Benjamin F. Edwards & Company's SRPT Position: Q2 2024 in Review

Benjamin F. Edwards & Company reduced its Sarepta Therapeutics (SRPT) stake by 92% in Q2 2024, selling an estimated $8.99K and leaving 6 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #2110.

Benjamin F. Edwards & Company first reported a position in SRPT in Q3 2014 and has held it in 13 quarters since. The position peaked at $322K in Q4 2022. 485 funds tracked by Wall St. Rank hold SRPT as of Q2 2024.

Benjamin F. Edwards & Company held 6 shares of Sarepta Therapeutics worth $1K as of Q2 2024.
Benjamin F. Edwards & Company sold 70 Sarepta Therapeutics shares in Q2 2024, an estimated $8.99K.
Sarepta Therapeutics made up ﹤0.01% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #2110 holding.
Benjamin F. Edwards & Company first reported a position in Sarepta Therapeutics in Q3 2014 and has held it in 13 quarters since.
Benjamin F. Edwards & Company's Sarepta Therapeutics position peaked at $322K in Q4 2022.
485 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.